Submitted by dcc on Mon, 2021-10-25 11:06 Study Title: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsCIRB: Pediatric CIRBLead Group: PEP-CTNStatus: ActiveReview Status: Available to Open
